

Contents

Executive Summary.....	6
Introduction and Disclaimer	8
Executive Mission and Strategic Alignment	8
Editorial Standards	11
Methodology in Brief.....	16
Authorship, Independence, and Reviewability	17
THE EMPAGLIFLOZIN REPORT	19
The EMPA-REG Outcome Trial	20
When the Treatment of Diabetes Changed.....	20
Why the EMPA-REG result mattered so much.....	22
1) The first major crack: The biology moved too fast.....	23
The post hoc biological explanations	25
Who built those explanations?.....	26
2) The statistical core of the problem: Non-assessable deaths.....	26
3) The geographic anomaly	27
4) The stroke paradox	28
5) The missing dose-response relationship.....	30
So, to summarize the anomalies:	31
Was this a benefit trial, or a safety trial repurposed after the fact?	32
The FDA Split Decision: the 12–11 vote	34
How the narrative was defended after approval	37
What do we see when we analyze the clinical data published AFTER EMPA-REG, between 2015 and 2026?	40
What this means for doctors and patients.....	50
The deeper lesson.....	51
Summary.....	52
Empagliflozin Sales 2025.....	53
Why This Report Matters for Key Stakeholders.....	53
For Regulators	53
For Ethics Committees	53

For Pharmacovigilance Teams	54
For Regulatory Affairs Teams.....	54
For Clinical Development Teams.....	54
For Marketing Teams	54
For CEOs and Senior Leadership	54
Appendices.....	55
Appendix 01: Example of a News Snippet of the FDA Decision on the Mortality benefit of Empagliflozin	56
Appendix 02: Letter from the Endocrine Society to the FDA serving as Testimony.....	59
Appendix 03: The Murky Water in the Healthcare Fishtank	61
Appendix 04: References	73
Ansilo Data Labs Report Launches in 2026.....	75



Executive Summary

Empagliflozin was presented to the medical world **as a breakthrough: a diabetes drug associated with a striking 38% reduction in cardiovascular death in the EMPA-REG OUTCOME trial.**

That claim mattered enormously. It helped elevate the drug into a major clinical and commercial asset, shaped professional enthusiasm, and contributed to its later stabilization within mainstream treatment narratives. This report examines whether that narrative **became cleaner, stronger, and more certain than the underlying record justified.**

The central finding is **not** that empagliflozin lacks value. Later evidence **supports meaningful benefits, particularly in heart failure and kidney disease.**

The central finding is narrower: **the original mortality story appears more fragile than the dominant narrative often suggested.** The report identifies multiple points of tension around EMPA-REG, including the unusually rapid timing of the claim, differential uncertainty around the classification of key deaths, regional inconsistency in stroke-related disease, and the absence of a convincing dose-response pattern. Taken together, these issues do not automatically invalidate the trial, but they do weaken the impression of a clean, decisive mortality miracle.

The report also finds that the narrative was not stabilized mainly by *detached external confirmation*. Much of the later literature that defended, extended, or biologically explained the original claim emerged from **a sponsor-linked interpretive ecosystem**. Mechanistic explanations, post hoc reframings, and supportive analyses often helped smooth over unresolved tensions rather than decisively settle them. The report's authorship audit makes that pattern visible: across the core papers used to stabilize the empagliflozin story, **financially aligned authors account for 83% to 100% of named authors in the sample shown.**


Regulators occupy an especially important position in this story. They are not pharmaceutical companies, and this report does not treat them as such. But regulators often make decisions on the basis of evidence packages assembled by sponsors, under conditions of uncertainty, time pressure, and practical constraint. In the empagliflozin case, the report argues that regulatory acceptance and independent clinical certainty were not the same thing. Once a narrow and uneasy approval was granted, *the wider medical system had a strong tendency to interpret that decision as stronger confirmation than it may actually have represented.*

Introduction and Disclaimer

Executive Mission and Strategic Alignment

Ansilo Data Labs (ADL) is the analytical intelligence division of Ansilo Global Enterprises. Its role is to produce **evidence-led reports** and decision tools that help readers navigate complex scientific, regulatory, and commercial landscapes with greater **clarity** and independence.

ADL is built on a simple premise: in healthcare and pharmaceuticals, important decisions are often shaped not only by what is **known**, but by what is **emphasized, omitted, delayed**, or framed in ways that **overstate certainty**. Our work is designed to examine these points of tension carefully, drawing together fragmented public evidence into structured, usable analysis.



Sources: 1. Horton R. Offline: What is medicine's 5 sigma? *Lancet*. 2015;385(9976):1380. doi:10.1016/S0140-6736(15)60696-1. 2. Angell M. Drug companies & doctors: a story of corruption. *N Y Rev Books*. 2009 Jan 15;56(1).

Figure 1: Published data requires careful evaluation

Published literature should not automatically be treated as the full evidentiary picture. The visible scientific record may reflect not only what was discovered, but also what was emphasized, published, repeated, and absorbed into mainstream interpretation.

At the heart of ADL is the belief that **decision quality** depends on **evidentiary quality**. When published data is **incomplete, selectively presented,** or interpreted through **conflicted incentives,** clinicians, patients, investors, and policymakers may inherit more confidence than the evidence can cleanly support.




Figure 2: The Anatomy of Influence

Clinical narratives are shaped by more than primary data alone. They are also influenced by the institutions and pathways through which evidence is presented, interpreted, and legitimized.


ADL exists to reduce these evidentiary asymmetries. This is both a **practical** and **ethical** undertaking. In the health sector, **distorted interpretation** does not remain abstract; it can shape **prescribing, regulation, standards of care, capital allocation,** and ultimately **patient outcomes.**

Why the EMPA-REG result mattered so much

To understand why EMPA-REG created such excitement, you must understand the background. For decades, medicine faced a grim reality: **nearly two-thirds of people with diabetes** died from cardiovascular complications.[5] Strokes, myocardial infarctions, and other vascular events drove enormous morbidity and mortality.

And despite all the focus on glucose control, lowering blood sugar alone **did not reliably translate into fewer cardiovascular deaths**.[6] Correcting blood sugar did not stop the heart attacks from happening.

Controlling blood sugar has historically failed to improve cardiovascular outcomes.



Sources: Zou et al. BMJ Open 2018; Hart et al. BMJ 2012; Miller et al. BMJ Open 2015.


Figure 14: Controlling blood sugar alone does not improve CV outcomes

That was the frustration. Doctors could improve glucose numbers, yet patients still died from heart disease. Trials targeting hyperglycemia repeatedly failed to demonstrate the kind of cardiovascular mortality benefit clinicians wanted.

So when EMPA-REG appeared to show a dramatic reduction in cardiovascular death, **the response was explosive**. The room was electrified.[1][3] A thirty-eight percent reduction is a massive number in literally any field of medicine. But in this specific context, diabetes and heart disease, it was just unheard of.[1][2]

It was described as a **breakthrough, a game changer, even the holy grail of diabetes care**.

Removing deaths of uncertain cause entirely eliminates Empagliflozin's statistical superiority.



Alzaid A. Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial. *Diabetes Technol Ther.* 2017;19(6):324-327. doi:10.1 (adapted from)

Figure 20: CV benefits disappears when 'mystery deaths' removed.

And yet those deaths were still counted as cardiovascular deaths under the trial's adjudication framework.[4][10] Because this specific trial was focused on tracking cardiovascular outcomes, the researchers just presumed that these mystery deaths were cardiovascular in origin. They just lumped them into the final tally. The uncomfortable truth is that when these mystery deaths were removed, the P value spikes, indicating that any remaining difference between the drug and the placebo is essentially indistinguishable from random noise.[4][10]

That matters enormously. Because when regulators examined what happened after removing those uncertain cases from the analysis, the dramatic mortality advantage was no longer persuasive.[10] The signal weakened substantially, and the apparent miracle looked far less secure. **This is one of the most serious concerns in the whole trial.** If a major headline benefit depends heavily on deaths whose causes were never clearly established, the result becomes much more fragile than the public narrative suggests.

3) The geographic anomaly

Then there is the regional inconsistency.


If a drug is truly acting through a robust and universal biological mechanism, you would expect broadly consistent benefit across human populations. But in EMPA-REG, the data were not evenly convincing across regions. [4]

Featured report: APRIL 2026:
EMPAGLIFLOZIN

**Multi-user Licencees receive early
notification of new publications**

a Narrative Friction Report

**WHEN THE CLINICAL
NARRATIVE OUTFRONS
THE EVIDENCE.**



PHARMACEUTICAL
REPORT APRIL 2026